Tag: Australian Market

Investment Thesis:

• Global re-open and vaccine roll-out acts as leverage for IDP Education.
• The company is expected to be benefitted from margin expansion (computer- based IELTS), network expansion (latest inclusion of IELTS test centres in Ireland, Poland, Chile and Peru and student placement offices in Pakistan and Canada).
• IDP’s English Language Testing stream (IELTS) has a strong reputation as the world’s most trusted English language test for study, work and migration.  
• Solid margin and strong earnings/revenue growth/strong cashflow generation is maintained by IDP.
• Strong management team.
• Growth opportunities at global level due to international student population and education industry. 
• Introduction and planned roll out of online IELTS delivery to provide opportunities for stronger growth.
• Strong balance sheet, with high liquidity. 
• Substantial margin opportunity is unlocked by potential restructuring with British Council  

Key Risks:

• Periodic growth cannot be predicted with IDP’s business model 
• Future economic lock-downs to Covid-19
• Risk of currency conversion
• In order to justify the valuations, high growth rate should be met  
• Threat of a new entrant or competition from the existing players

Key Highlights:

• FY21 Earnings were impacted by the pandemic, with adjusted EBIT of $71.8m, which was down by 31% over the pcp (previous corresponding period).
• IELTS volumes were up 5% despite ongoing disruptions at the operational level due to the on-going pandemic and government-imposed restrictions.
• The placement volumes of students to countries except Australia reduced by 12% relative to FY20 in spite of the uncertainties that were associated with travel and physical learning
• Digital Marketing revenue jumped 8% to $30m driven by institutional clients looking up to IDP’s global digital platform for marketing and data insights.
• Strategic acquisition in a growth market in British Council’s IELTS operation in India for £130m, which is highly strategic for IDP and provides several benefits like increased exposure to the high-growth Indian IELTS market; simplified distribution arrangements providing the opportunity to simplify and improve the delivery of IELTS to test takers in India.
• The highlights by segments are stated as below:

• English Language Testing: Revenue of $325.6m, which was up by 8%
• Student Placement: Revenue of $143.3, was 22% lower; for Australia, revenue was 34% weaker at $59.7m, due to border closures relating to Covid-19. For Multi-destination, revenue was -17% weaker at $83.5m.
• English Language Teaching: Revenue of $20.2m, which is -23% lower
• Digital Marketing and Events: Revenue of $36.4m, which is -2% lower
• Others: Revenue of $3.2m was -20% weaker

Company Profile:

IDP Education Ltd (IEL) offers: (i) Student placement: student recruitment/placement in 93 offices across 30 countries into  approximately 600 universities, schools and colleges globally in 5 destination countries; and (ii) co-owner of IELTS, an English language proficiency test which foreigners must pass in order to obtain certain visas and permanent residency in Australia. IEL is 50% owned by Education Australia Ltd – a business in which 38 Australian universities own a 50.1% stake.

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Investment Thesis:

• Increased demand for health care services due to ageing population of Australia, thereby contributing increased dependence on private health care insurers. NHF offers exposure to the business model of providing a funding mechanism for the high-growth health care sector.
• Healthcare expenditure is expected to rise by 5-10% per annum, so government cannot offer healthcare services to people without increase in tax.
• The average premium rates increased at the rate of 5 – 6% per annum. 
• Policyholder growth and exposure to speed up the investments, NHF is expected to offer double-digit growth in medium term.
• Strong members in management.
• Chalking out budget plan, which improves the company’s expense ratio. 
• PHI (Protected Health Information) is promoted by giving incentives and benefits. 
• Joining with Tasly Holdings (Chinese Pharmaceutical Company) in Joint Venture and making international presence through the same.

Key Risks:

• Increase in competition among top 6 players
• Putting policy growth targets at risk 
• Marketing expenses are anticipated to go high, thereby straining earnings growth.
• Unexpected decline in policyholders in spite of providing incentives 
• Rapid increase in healthcare spending and health services demand from people have left Australian Government struggling.
• Registered health insurance firms are unable to increase premium rates without prior approval from the Government/Minister for Health/PHIAC/APRA. Because of this, NHF’s ROE and margins would be exposed to political process and pressures if the company makes large profits.
• Regulatory changes including tax incentives and benefits which encourage take up of PHI. 
• Due to poor insurance policy design, aging population, and costs of new medical equipment, procedures and treatments; lapse rates and claims inflation would be higher than expected.
• Negotiations not done rightly with healthcare providers (private hospital operators) which may result into unfavorable contractual terms;
• Investment returns might be lower than expected.

Key Highlights:

• nib holdings Ltd. (NHF) reported strong FY21 results in spite of Covid-19, however it was in line with management expectations
• Revenue grew by +2.9% to $2.6bn and Group operating profit (UOP) of $204.9m, which is up by 39.5%
• NPAT of $160.5m was mainly driven by net investment income of $51.8m.
• Statutory EPS of 35.2 cents, which was +82.4% higher.
• ROIC of 19.1% which was similar to pre-pandemic levels.
• Final dividend of 14cps fully franked (up from 4 cents), which brings the full year dividend to 24cps.

Company Profile:

nib Holdings Limited (NHF) is the Australian private health insurer. NHF operates in four divisions which are private health insurance, life insurance, travel insurance and related health care activities.

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Investment Thesis :

• Holds a leading positions in Australia, France and Scandinavia.
•  Earnings will begin to rise in FY22-24 as a result of pent-up demand on waiting lists.
•   Has a well-diversified portfolio with a large scale.
• Australia’s largest private hospital operator, with strong industry fundamentals  
• Favourable macro-industry trends include an ageing and growing population, the spread of chronic disease, and more innovation, treatment, and technology, all of which are driving demand to private hospital.
• Supportive government policy (tax incentive for people to get private health insurance). 
• Ongoing brownfield program driving earnings and offshore earnings growth
• Significant international operation paves way for the firm to grow internationally in near future.
•  Attractive industry dynamics with high entry barriers for new firms.

Key Risks:

• Competitive risk (new hospitals, new beds), from listed and unlisted hospital operators
• Brownfield projects fail to deliver the earnings uplift.
• Cost pressures (negotiating price increases with private health insurance companies).
• Government policy on private health insurance is changing.
• Execution risk (able to get the uplift in earnings from brownfield projects).
• Snap economic lockdowns due to Covid-19
• Currency risk

Key financial highlights of year2021:

In relative to the previous corresponding period i.e pcp (herein pcp is year 2020)

• During the year 2021, RHC revenue increased by 3.9% to $12.4bn.
• The increase in revenue was driven by strong earning growth across all of its geographical segments-i.e from Asia Pacific, UK and Europe.
• In Asia Pacific, revenue from patients increased by 7.8% to $5.4bn reflecting strong growth in surgical admission (2) In U.K, revenue increased by 10.2% to $1,024.1m and included payments from the NHSE of $417.6m representing net cost recovery for services provided by Ramsay to the NHSE during the year (3) Europe revenue increased by 6.9% to $6,839.9m and included government grants of $428.3m and was impacted by 80m euros from the sale of a portfolio of nine German hospitals in 1H21
• EBIT increased by 29.1% to $1.1bn and statutory profit increased by 58.1% to $449m, reflecting a strong increase in admissions.
• The Board declared a fully franked final dividend of 103cps, bringing the FY21 dividend to 151.5cps (up by 142.4 %) and representing a payout ratio of 79 percent of statutory profit.
• During the underlying period ROCE improved by 60bps to 9.3% and ROIC gained by 260bps to 7%.
• Operating cash flow fell by 11.9 % to $1.5 billion, owing to changes in working capital as a result of cash loans from the French government while FCF fell by 14.8 percent to $85,
• Financial metrics improved, with net debt (excluding lease liabilities) fallen by 15 % to $2.4 billion, lowering leverage to 3.7 times from 4.4 times. 

Company Profile:

Ramsay Health Care Ltd (RHC) is a company that provides medical services. RHC has hospitals, day surgery centres, treatment facilities, rehabilitation centres, and psychiatric units all around the world. It has about 500 sites throughout Australia, the United Kingdom, France, Sweden, Norway, Denmark, Germany, Indonesia, Malaysia, Hong Kong, Italy, and the Nordic countries.

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.